Teva Pharmaceutical Industries Ltd. has agreed to pay $450 million to resolve allegations it used charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay kickbacks to boost sales of its multiple sclerosis drug Copaxone and conspired to fix prices for generic drugs. The two settlements announced by DOJ on Thursday included one for $425 million resolving a lawsuit filed in federal court in Boston in 2020 as part of an industry-wide probe of drugmakers' financial support of patient assistance charities.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
